MAIA (MAIA Biotechnology) GF Value : $0.00 (As of Mar. 24, 2025)

View and export this data going back to 2022. Start your Free Trial

What is MAIA Biotechnology GF Value?

As of today (2025-03-24), MAIA Biotechnology's share price is $1.67. MAIA Biotechnology's GF Value is $0.00. Therefore, MAIA Biotechnology's Price-to-GF-Value for today is . Based on the relationship between the current stock price and the GF Value, GuruFocus believes MAIA Biotechnology is Not Valued.

The GF Value represents the intrinsic value of a stock, determined using GuruFocus' proprietary methodology. The GF Value Line on our stock Summary page provides an estimate of the stock’s fair-trading value.

To calculate this value, GuruFocus follows these steps:

We analyze historical correlations between the stock price and key business performance metrics, such as revenue, earnings, cash flow, and book value.
We identify the metrics that have the strongest historical correlation with the stock price and determine the historical multiples at which the stock has traded relative to these metrics.
Using these historical multiples as a reference, we estimate the stock's fair value while accounting for future business growth. Adjustments may be made based on the company’s past returns and growth trends.

GuruFocus believes that the GF Value Line represents the fair value at which a stock should trade. Stock prices typically fluctuate around this line. If a stock’s price is significantly above the GF Value Line, it is considered overvalued, and its future returns are likely to be lower. Conversely, if the stock price is significantly below the GF Value Line, its future returns are likely to be higher.

Please note that "Possible Value Trap, Think Twice" applies to companies that appear significantly undervalued but are either experiencing a long-term business decline or facing financial distress.

MAIA Biotechnology (AMEX:MAIA) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 ratings:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" applies to companies that appear significantly undervalued but are either experiencing a long-term business decline or facing financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) A sufficient margin of safety exists only when the stock is undervalued.

MAIA Biotechnology's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	1.67	/	0.00
	=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MAIA Biotechnology GF Value Related Terms

Thank you for viewing the detailed overview of MAIA Biotechnology's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

MAIA Biotechnology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MAIA Biotechnology Inc (AMEX:MAIA) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

444 West Lake Street, Suite 1700, Chicago, IL, USA, 06060

Website

https://www.maiabiotech.com

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.

Executives

Stan Smith	director	444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Ramiro Guerrero	director	444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Steven M Chaouki	director	C/O TRANSUNION, 555 WEST ADAMS STREET, CHICAGO IL 60661
Cristian Luput	director	444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Ngar Yee Louie	director, 10 percent owner	444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Vlad Vitoc	director, 10 percent owner, officer: Chief Executive Officer	444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Joseph F Mcguire	officer: Chief Financial Officer	6670 SPRINGLAKE ROAD, KEYSTONE HEIGHTS FL 32656
Jean-manasse Theagene	director	500 PLACE D ARMES, SUITE 1800, MONTREAL A8 H2Y 2W2
Sergei Gryaznov	officer: Chief Scientific Officer	444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Laurentiu Vlad	director	444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Mihail Obrocea	officer: Chief Medical Officer	444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606